Nanyang Biologics

Executive Summary

Nanyang Biologics is a Singapore-based preclinical biotech leveraging AI-driven deep technology to discover therapeutics and nutraceuticals from natural molecular insights. Focused on metabolic health, inflammation, and oncology, the company integrates biological, chemical, and botanical data to accelerate early-stage drug discovery. Founded in 2020, it aims to extend healthspan through scientifically validated, nature-inspired solutions. With a platform approach and operations in Singapore, Nanyang is well-positioned to capitalize on growing interest in AI-enabled drug discovery and natural product-based therapies. The company is private and has not disclosed funding or valuation, suggesting an early stage of development. Its preclinical stage indicates significant upside potential if candidates advance, but also high risk. The team's expertise in combining AI with natural products could yield differentiated assets. Near-term focus will be on advancing lead candidates into clinical trials and securing additional partnerships or financing.

Upcoming Catalysts (preview)

• Q3 2026Phase I trial initiation for lead metabolic health candidate60% success
• Q4 2026Series A funding round closing70% success
• Q2 2026Preclinical data publication on inflammation or oncology program75% success